Amarin Corp Plc (AMRN)

[Atom0aks]

The NLA advisory looks like a pretty narrow "label " to me .
I hope AMRN gets a wider label recommended at Adcom

https://www.lipid.org/nla/nla-position-use-icosapent-ethyl-high-and-very-high-risk-patients

Established ASCVD plus 1 risk factor ...or Diabetic plus 1 risk factor .

It's the additional 1 risk factor that limits this advisory IMHO .

I think it should be all CAD patients on Statins and all Diabetics
JMO

Kiwi

But it sounds like NLA simply used the exact same wording as REDUCE-IT when describing the primary and secondary prevention groups?

Among the patients who underwent randomization, 70.7% were enrolled on the basis of secondary prevention (i.e., patients had established cardiovascular disease) and 29.3% on the basis of primary prevention (i.e., patients had diabetes mellitus and at least one additional risk factor).

Source: https://www.nejm.org/doi/full/10.1056/nejmoa1812792